IL33 and Parkinson disease: We observed dysfunction in lipid metabolism and neuroinflammation in the PD mouse model, while plasmalogen‐based nanoparticles were able to attenuate certain inflammation markers (IL‐6, IL‐33, and TNF‐α) and restore lipid metabolism to levels comparable to those seen in wild‐type healthy mice.